Clinical trial design for cutaneous neurofibromas

Area of Science:

• Dermatology
• Clinical Trial Design
• Neurofibromatosis Research

Background:

• Multiple clinical trials for cutaneous neurofibromas (cNF) have not led to significant care improvements.
• There is a need to optimize clinical trial design for cNF to accelerate therapeutic development.

Purpose of the Study:

• Define key considerations for designing clinical trials for cNF.
• Summarize existing data relevant to cNF trial design.
• Provide consensus recommendations to expedite therapy development for cNF.

Main Methods:

• A multidisciplinary subgroup of experts reviewed existing data on cNF and other skin disease trials.
• Discussions focused on identifying priority issues for efficient and effective clinical trial design.
• Consensus was reached on key factors influencing trial design and development.

Main Results:

• Identified 2 natural history studies, 4 priority outcome measures, and 6 patient-reported outcome tools for cNF trials.
• Key factors for trial design include intervention initiation time, patient eligibility, mechanism of action, administration route, safety monitoring, and regulatory interactions.
• Patient age is a critical factor influencing trial design and development pathways.

Conclusions:

• Standardizing endpoints and measurement methods for cNF is crucial for therapeutic advancement.
• Leveraging technological advances and outcome tools from other skin diseases can benefit cNF studies.
• Optimized clinical trial design is essential to accelerate the development of effective cNF therapies.